SIRTUINS, NEW POTENTIAL TARGETS FOR HIV-THERAPY
Gnemmi I., Riva B., Di Rosa M., Nunnari G., Galli U., Genazzani A., Condorelli F., Canonico P. |
ANTITUMOR ACTIVITY OF PIMASERTIB, A SELECTIVE MEK 1/2 INHIBITOR, IN COMBINATION WITH PI3K/MTOR INHIBITORS OR WITH MULTI-TARGETED KINASE INHIBITORS IN PIMASERTIB-RESISTANT HUMAN LUNG AND COLORECTAL CANCER CELLS
Ciuffreda L., Ferraiolo F., Martinelli E., Troiani T., Morgillo F., Costantino S., Martini G., Ciardiello F., Berrino L. |
CIRCULATING CANCER STEM CELL PROGENY: CORRELATION WITH “NICHE” CANCER STEM CELLS AND MONITORING OF ANTICANCER DRUG TREATMENT IN NON SMALL CELL LUNG CARCINOMA
Malara N., Trunzo V., Givigliano F., Aprigliano S., Raso C., Gliozzi M., Marchese A., Mollace V. |
SYNERGIC ANTITUMOR ACTIVITY OF DPE, A POLYPHENOL OF EXTRA VIRGIN OLIVE OIL, AND CETUXIMAB IN COLON CANCER
Terzuoli E., Donnini S., Ziche M. |
PGE2 INDUCES THE ANGIOGENIC SWITCH IN METASTATIC CASTRATION RESISTANT PROSTATE TUMOR CELLS TARGETING ANGIOGENIC MIRNA
Terzuoli E., Donnini S., Villari D., Ziche M. |
INVESTIGATIONS OF THE EFFECT OF A CYCLIC RGD PEPTIDOMIMETIC ON CELL PROLIFERATION, MIGRATION AND ANGIOGENIC ACTIVITY IN HUMAN ENDOTHELIAL CELLS
Schembri L., Fanelli R., Piarulli U., Scanzano A., Cosentino M., Marino F. |
NOVEL THERAPEUTIC STRATEGY TO PREVENT CHEMOTHERAPY-INDUCED PERSISTENT SENSORY NEUROPATHY BY TRPA1 BLOCKADE
Trevisan dos Santos G., Materazzi S., Fusi C., Altomare A., Aldini G., Lodovici M., Patacchini R., Geppetti P., Nassini R. |
BIOLOGICAL CHARACTERIZATION OF NANOCOMPOSITE HYDROGELS
Finetti F., Solito R., Pasqui D., Barbucci R., Donnini S., Morbidelli L., Ziche M. |
RHO0 CELLS AND METABOLOMIC APPROACH TO EXPLOIT MECHANISM OF RESISTANCE TO CISPLATIN IN OVARIAN CANCER CELL LINES
Catanzaro D., Montopoli M., Bellanda M., Frezza C., Froldi G., Ragazzi E., Caparrotta L. |
USE OF HEALTH CARE ADMINISTRATIVE DATABASES TO ESTIMATE THE HEALTH CARE BURDEN OF BONE OR BONE MARROW METASTATIC DISEASE IN BREAST CANCER PATIENTS: A POPULATION-BASED STUDY
Mantovani L., Scalone L., Furneri G., Ciampichini R., Cortesi P., Fornari C., Madotto F., Chiodini V., Cesana G. |
USE OF HEALTH CARE ADMINISTRATIVE DATABASES TO ESTIMATE THE BURDEN OF BREAST CANCER
Ciampichini R., Furneri G., Scalone L., Cortesi P., Fornari C., Madotto F., Chiodini V., Mantovani L., Cesana G. |
A META-ANALYSIS OF PIPERACILLIN/TAZOBACTAM AND CARBAPENEMS IN CANCER PATIENTS WITH FEBRILE NEUTROPENIA
Smeriglio A., Trombetta D., Tomaino A. |
ROLE OF PROSTAGLANDIN E2 IN EGFR MEDIATED DU145 PROSTATE CANCER GROWTH AND EPITHELIAL MESENCHYMAL TRANSITION
Finetti F., Bazzani L., Villari D., Ziche M., Donnini S. |
TARGET-HOPPING: A USEFUL APPROACH TO IDENTIFY NOVEL EPH RECEPTOR ANTAGONISTS
Giorgio C., Hassan-Mohamed I., Pala D., Russo S., Lodola A., Incerti M., Barocelli E., Tognolini M. |
INITIAL CHARACTERIZATION OF THE METABOLIC STABILITY OF THE SELECTIVE AND POTENT GLUTATHIONE TRANSFERASE P1-1 INHIBITOR 6-(7-NITRO-2,1,3-BENZOXADIAZOL-4-YLTHIO)HEXANOL (NBDHEX) IN LIVER MICROSOMES AND CYTOSOL: AN INTERSPECIES COMPARISON
Calderan L., Dalzoppo D., Ibrahimaj J., Orsetti A., Rosato A., Geroni C., Caccuri A., Quintieri L. |
SCREENING OF SULFASALAZINE ANALOGUES FOR INHIBITION OF HUMAN GLUTATHIONE TRANSFERASE P1-1, A TARGET FOR ANTICANCER THERAPY
Calderan L., Castellano S., Balzano A., Saggioro D., Ciancietta A., Deganutti G., Milite C., Sbardella G., Rossi C., Moro S., Quintieri L. |
DISCOVERY AND DEVELOPMENT OF EPH-EPHRIN ANTAGONISTS ENDOWED WITH ANTIANGIOGENIC PROPERTIES
Hassan-Mohamed I., Giorgio C., Russo S., Incerti M., Pala D., Lodola A., Barocelli E., Tognolini M. |
VISFATIN: NEW ROLE AS CYTOKINE IN TUMOUR MICROENVIRONMENT
Grolla A., Torretta S., Canonico P., Genazzani A. |
AMPK MEDIATES THE ANTI-PROLIFERATIVE EFFECTS OF CELECOXIB IN CML CELL LINES
Riva B., Gnemmi I., Condorelli F., Canonico P. |
MECHANISMS OF TOXICITY AND METABOLISM OF THIOPURINES IN NON TUMOR HUMAN HEPATIC AND INTESTINAL CELL LINES
Stocco G., Pelin M., De Iudicibus S., Taboga E., Pellizzari G., Favretto D., Decorti G. |
COSTS AND OUTCOMES OF PATIENTS WITH HAEMOPHILIA A (HA) AND FACTOR VIII INHIBITORS TREATMENT: THE IMMUNE TOLERANCE AND ECONOMICS RETROSPECTIVE REGISTRY (ITER) RESULTS
Gringeri A., Scalone L., Cortesi P., Rocino A., Mantovani L. |
COST-EFFECTIVENESS OF PROPHYLAXIS WITH AN ANTI-INHIBITOR COMPLEX CONCENTRATE IN PATIENTS WITH HAEMOPHILIA AND INHIBITORS: RESULTS FROM PRO-FEIBA STUDY
Gringeri A., Leissinger C., Cortesi P., Cristiani M., Fusco F., Mantovani L. |
RELATIONSHIP BETWEEN CLINICAL SEVERITY AND HEALTH RELATED QUALITY OF LIFE IN CHRONIC LIVER DISEASES
Scalone L., Cortesi P., Ciampichini R., Okolicsanyi S., Rota M., Ciaccio A., Ideo G., Colledan M., Belli L., Cesana G., Mantovani L., Strazzabosco M. |
THE EFFECT OF ARA-C TREATMENT ON HEMATOPOIETIC STEM CELL EXPANSION AND LEUKEMOGENESIS IN A MOUSE MODEL OF CEBPA MUTANT ACUTE MYELOID LEUKEMIA
Cimino M., Venanzi A., Frammartino T., Sorcini D., Biagioli M., Bruscoli S., Riccardi C., Bereshchenko O. |
CLINICAL RELEVANCE OF THE ASSESSMENT OF DEFERASIROX TROUGH LEVELS IN THALASSEMIA PATIENTS
Massano D., De Francia S., Longo F., Sandri A., Piccione F., Pirro E., Allegra S., D'Avolio A., Piga A. |
THERAPEUTIC EQUIVALENCE, EFFICACY AND SAFETY OF EPOETIN ALFA ORIGINATOR AND BIOSIMILAR IN THE TREATMENT OF ANEMIA IN CHRONIC KIDNEY DISEASE PATIENTS RECEIVING DIALYSIS
Busa G., Tasca F., Tonato G., Lentini P., Dell'Aquila R. |
SURVIVIN-DIRECTED MOLECULAR BEACON AS POTENTIAL “THERANOSTIC AGENT” IN MELANOMA CELLS
Carpi S., Adinolfi B., Fogli S., Giannetti A., Tombelli S., Baldini F., Vanni A., Martinotti E., Breschi M., Pellegrino M., Nieri P. |
EFFECT OF EFAVIRENZ AND NEVIRAPINE ON HIV REVERSE TRANSCRIPTASE ACTIVITY THROUGH A NOVEL, PCR-BASED ASSAY
Frezza C., Marino Merlo F., Mastino A., Macchi B. |
PHARMACOKINETICS OF ULIFLOXACIN, THE ACTIVE METABOLITE OF PRULIFLOXACIN, INTO HUMAN MUSCLE.
Cerretani D., Giorgi G., Fiaschi A., Urso R., Crainz E. |
INHALATED DRUG DELIVERY SYSTEMS TO TARGET ALVEOLAR MACROPHAGES FOR TUBERCULOSIS THERAPY: DESIGN OF SAFE SLM LOADED WITH RIFAMPICIN
Maretti E., Iannuccelli V., Leo E., Bondi M., Croce M., Sacchetti F., Rossi T. |
TDM-GUIDED CLINICAL PHARMACOLOGICAL ADVICES FOR PERSONALIZATION OF ANTIMICROBIAL TREATMENT IN CRITICALLY ILL CHILDREN
Cojutti P., Pea F. |
ERADICATION OF HELICOBACTER PYLORI INFECTION IN ADULT: IS SEQUENTIAL THERAPY THE TREATMENT OF CHOICE? A SYSTEMATIC REVIEW AND META-ANALYSIS
Gatta L., Vaira D., Scarpignato C. |
INCREASED TGF ALPHA AS A MECHANISM OF ACQUIRED RESISTANCE TO THE ANTI-EGFR INHIBITOR CETUXIMAB THROUGH EGFR-MET INTERACTION AND ACTIVATION OF MET SIGNALING IN COLON CANCER CELLS
Ferraiolo F., Ciuffreda L., Troiani T., Martinelli E., De Palma R., Ciardiello F., Berrino L. |
